Navigation Links
EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board

RICHMOND, Virginia, ROSH HA'AYIN, Israel, June 16 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for advanced chronic wound management, recently announced the formation of its Scientific Advisory Board (SAB) comprised of world-renowned scientists, researchers and practitioners with diversified expertise in chronic wounds. The Company named David Armstrong, DPM PhD, Rob Kirsner, MD, PhD, Diane L. Krasner, PhD RN, FAAN, Joseph L. Mills, MD, PhD and Itzhak (Tzaki) Siev-Ner, MD as members of the SAB. David Armstrong will chair the Advisory Board. The SAB will meet regularly to provide EnzySurge with scientific and clinical guidance for its research, regulatory and commercialization activities.

"We are delighted with the caliber of scientists and practitioners who have decided to join our SAB said Amir Shiner, CEO of EnzySurge. "They are not only key opinion leaders in the various areas relevant to our field, but they also all bring industry experience, which will be instrumental as we move toward commercializing our products. The individual and collective expertise of our Scientific Advisory Board in diabetic foot, venous and pressure ulcers, biotechnology, clinical development and wound care standards of care, will no doubt accelerate our research and development and will ensure we address the most vital needs of our target market."

EnzySurge's DermaStream(TM) product line is based on its proprietary Continuous Streaming Therapy (CST(TM)) technology. The comprehensive system continuously streams a fresh supply of active solutions to a controlled wound environment. EnzySurge has developed a series of bio-active therapeutic solutions to facilitate safe and effective healing of chronic wounds, from debridement, through regeneration to closure. The DermaStream family of products is designed to treat all forms of chronic wounds including diabetic ulcers, venous ulcers and pressure ulcers. DermaStream touch-free treatments result in faster, more effective and painless wound healing in the hospital, clinics, nursing homes and at home.

The members of EnzySurge's Scientific Advisory Board include:

Chairman, David G. Armstrong DPM, MD, PhD is Professor of Surgery and Associate Dean at the Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science in Chicago. Armstrong is Director of the Center for Lower Extremity Ambulatory Research (CLEAR). He has produced more than 230 peer-reviewed research papers in more than two dozen scholarly medical journals as well as over two dozen book chapters and is co-Editor of the American Diabetes Association (ADA)'s Clinical Care of the Diabetic Foot. Armstrong was selected as one of the first six International Wound Care Ambassadors and is the recipient of numerous awards by national and international medical organizations. He is past Chair of Scientific Sessions for the ADA's Foot Care Council, and a past member of the National Board of Directors of the ADA. Armstrong is the founder and co-chair of the International Diabetic Foot Conference (DF-Con), the largest annual international symposium on the diabetic foot in the world.

Rob Kirsner MD, PhD is a Professor and Vice Chairman of the School of Medicine, University of Miami, School of Dermatology and Cutaneous Surgery. Dr. Kirsner received certifications from the National Board of Medical Examiners, American Board of Dermatology and American Academy of Wound Management. Dr. Kirsner's clinical interests are in wound healing, leg ulcers, skin cancer, medical dermatology and cutaneous surgery. He is active in research in wound healing, health care policy, dermatoepidemiology, inpatient dermatology and cancer control and prevention.

Diane L. Krasner, PhD, RN, FAAN is a Wound & Skin Care Consultant based in York, Pennsylvania. She works part-time as the WOCN / Special Projects Nurse at Rest Haven - York. She has been the lead co-editor of Chronic Wound Care: A Clinical Source Book for Healthcare Professionals since the first edition was published in 1991. Dr. Krasner is on the editorial boards of Wounds, The International Journal of Wound Care and World Wide Wounds. Dr. Krasner is a Board Certified Legal Nurse Consultant and she serves as an expert witness in legal cases involving wound and skin care.

Joseph L. Mills, MD, PhD serves as Chief of the Division of Vascular Surgery, Professor of Surgery, and Director of the Vascular Surgery Training Program at the University of Arizona Health Sciences Center, Tucson, Arizona. Dr. Mills is certified by the American Board of Surgery with Special Qualifications in Vascular Surgery. His areas of active research interest include open and endovascular treatment of aortic aneurysms, noninvasive evaluation of peripheral vascular disease, hemodialysis access, treatment of carotid and vertebral artery disease to prevent stroke, diabetic foot problems, limb salvage using endovascular techniques and leg bypass surgery, and treatment and prevention of graft stenosis. Dr. Mills has published over 130 manuscripts, produced five films of complex operative techniques, and edited three major textbooks.

Itzhak (Tzaki) Siev-Ner, MD is the Chairman of the Israeli Diabetic Foot Society. Siev-Ner serves as the Director of the Orthopedic Rehabilitation department in the Sheba Medical Center, Tel-Hashomer, Israel. He is Board certified both in Orthopedic Surgery and Physical and Rehabilitation Medicine. His main practice is prevention and treatment (conservative and surgical) of Diabetic Foot Ulcers, chronic wounds, amputations and the rehabilitation of these conditions. He is involved in research of different aspects of wound healing.

About EnzySurge

EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge's flagship DermaStream(TM) platform based on the proprietary Continuous Streaming Therapy (CST(TM)) offers a new and unique wound treatment modality by continuously streaming a fresh supply of advanced bio-active therapeutic solutions to a controlled wound environment. DermaStream(TM) is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound treatment cycle from debridement, through regeneration to wound closure. DermaStream(TM) was designed for use in hospitals, clinics, nursing homes and for home care.

EnzySurge is committed to the development and delivery of innovative solutions that improve the quality of life of chronic-wound patients by shortening healing time, preventing hospitalization and reducing treatment costs. visit

PR Contacts:

Boaz Gruener, Director of Marketing and Business Development


SOURCE EnzySurge Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
2. EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
3. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
4. Ortho Evra Patch Makers Settling Cases
5. New research shows that iPods do not interfere with cardiac pacemakers
6. Bioscience Group Warns Policymakers Against Complacency
7. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
8. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
9. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. BioMarin to Present at the BioCentury NewsMakers Conference
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):